Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (March 2021)
14 slides from Astrazeneca's investor day presentation, Mar 25, 2021
Slide 1: Respiratory & Immunology: near-term opportunities
Break-out session 4 Respiratory & Immunology: near- term opportunities Richard Marshall, Senior Vice President, late-stage R&D Pablo Panella, Senior Vice President, Head of Respiratory & Immunology, BioPharmaceuticals Business Unit Gerard O’Malley, Global Franchise Head, tezepelumab, late-stage R&D
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: Respiratory diseases: under recognised and under treated
Respiratory diseases Under recognised and under treated Asthma COPD1 Evidence to transform care 339m 176m 384m patients attacks patients worldwide worldwide each year 3rd • ICS2/formoterol preferred anti- cause of death in 2020, more deaths than cancer each year inflammatory reliever in asthma >50%
Slide 4: Breztri and PT027: strength in inhaled medicines
Breztri and PT027: strength in inhaled medicines Next-generation medicines for mild and moderate disease Breztri: poised to be a strong competitor PT027: first ICS/SABA1 in the fastest-growing COPD class rescue medicine for the US COPD patients, millions Pack units sold, FY 2020, China Launch aligne
Slide 5: Fasenra and tezepelumab: asthma leadership
Fasenra and tezepelumab: asthma leadership Greater use of biologics anticipated in severe asthma Significant opportunity to grow Tezepelumab5: positive NAVIGATOR Phase III data in broad population biopenetration in severe asthma 3 ↓70% (95% CI: 60, 78) ↓68% (95% CI: 58, 75) Fasenra remains key 2.66
Slide 6: Increasing presence in immunology
Increasing presence in immunology Pursuing leadership, starting with lupus Near term • Enter rheumatology with anifrolumab in systemic lupus erythematosus Adaptive Immunity Innate Immunity Tissue Mechanisms Medium term T regulatory cell B-cell humoral T effector cell Inflammatory myeloid cell Nuclei
Slide 7: Anifrolumab: first new SLE treatment in 10 years
Anifrolumab: first new SLE1 treatment in 10 years Potential first-in-class MOA2 with robust efficacy. LCM plans include LN3, CLE4, myositis TULIP 2 Phase III trial BICLA5 Pooled TULIP 1/2 Phase III trials Pooled TULIP 1/2 Phase III trials scores, overall responders Skin CLASI6 response OCS sparing w
Slide 8: Full pipeline and news flow
Full pipeline and news flow Upcoming milestones and key readouts Respiratory and Immunology: near-term opportunities Upcoming milestones Phase II Phase III Regulatory review H1 2021 anifrolumab AZD7442 Fasenra MANDARA anifrolumab TULIP Type I IFN1 receptor long-acting antibody combination IL5R Type
Slide 9: Questions & Answers
Questions & Answers To ask a question Webinar Click ’Raise Hand’ (preferred): or type your question into the Q&A box (alternative) Phone *6 - Toggle mute/unmute *9 - Raise hand 9
Slide 10: Appendix
Appendix 10
Slide 11: Publications
Publications anifrolumab Trial Congress/journal Title Author Citation European League Against Rheumatism (EULAR) 2020, Oral Presentation: Early and sustained responses with anifrolumab treatment in patients with active Morand EF, Furie R, TULIP 1 and 2 2020;79(suppl. 1):2-3. Annals of the Rheumatic
Slide 12: Publications, continued
Publications, continued Fasenra Trial Congress/journal Title Author Citation American Academy of Allergy, Asthma & Immunology (AAAAI) Poster: Elimination of Oral Corticosteroids (OCS) with (or Following) Benralizumab Treatment in OCS- Menzies-Gow A, Gurnell 2021;147(2 PONENTE 2021, The Journal of Al
Slide 13: Publications, continued
Publications, continued Tezepelumab, continued Trial Congress/journal Title Author Citation American Academy of Allergy, Asthma & Immunology (AAAAI) Oral Presentation: Tezepelumab efficacy in patients with allergic and non-allergic asthma: a post hoc Corren J, Colice G, 2021;147(2 PATHWAY 2021, The
Slide 14: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availabl